Definitive Contract HHSO100201500024C
Award Date
9/30/15
Potential Completion Date
12/14/19
Potential Value
$6.8M
Awardee
Indevr, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Boulder, CO 80301, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a one-year service agreement between the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Indevr, Inc., a manufacturer of goods and provider of analytical technologies for vaccines and biotherapeutics. The $6,000 firm fixed price contract is for an Indevr VirocyT2100 instrument, and includes unlimited phone/internet support, all parts, labor and travel for up to three field service calls, and one preventive maintenance visit. The...
This federal contract award, with ID HHSN272201100746P, was made by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to Indevr, Inc., a manufacturer of goods and provider of analytical technologies for vaccine characterization and production. The $68,860.00 firm fixed-price purchase order is for the provision of goods and services such as multiplex microarray assay platforms, automated hemagglutination analyzers, coronavirus seroassay kits,...
The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm-fixed-price purchase order contract to Indevr, Inc., a manufacturer of goods and provider of analytical technologies, for a Multiplex Microarray Assay Imaging System. The contract, valued at $84,895.00, will be performed in Boulder, Colorado and has a completion date of June 1, 2024. Indevr, a for-profit organization, has provided similar...
This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Indevr, Inc., a for-profit manufacturer of goods and provider of progressive analytical technologies. The $195,200.00 contract is for the delivery of 2 VIRUS COUNTERS MACHINES - MODEL VIROCYT2100. This award has a total small business set aside designation. Indevr, Inc. has previously held other federal contracts and grants with agencies including the National Institutes of Health's National Institute...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the NIAID Division of Microbiology and Infectious Diseases (DMID) Influenza Vaccine Project (H5N1) to develop influenza variant virus vaccines. The contract has a ceiling value of $19,476,349.00 and is a Delivery Order with a Cost Plus Fixed Fee...
This is a $749,999.01 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Red Queen Therapeutics Inc., a self-certified small disadvantaged business. The contract is for research and development of a rapid response platform for the development of a pan-influenza virus fusion inhibitor for the treatment of influenza virus infections. This contract is not set aside and has an ultimate completion date of...
<p>This is a $749,165.00 firm fixed price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Eradivir Inc. The contract is for Eradivir to complete a package of GLP-compliant nonclinical safety studies that will support a successful initial IND (Investigational New Drug) application. The contract has an ultimate completion date of November 15, 2024. No set-aside designation was used for this award.</p>
This $34,714,763.00 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Detect Inc. to advance the development of a second-generation, multi-analyte molecular SARS-CoV-2 and influenza A/B test that has a reduced time to result and increased sensitivity for use at home or in a point-of-care setting. The contract is not set aside. The award references a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research...
This is a $4,916,990 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Peraton Inc. for the Viral Bioinformatics Resource Center. The contract has a potential ceiling value of $23,385,247.30 and runs through November 14, 2019. Peraton, the prime contractor, has partnered with several major subcontractors including Oracle America, Inc., Vecna Medical, J. Craig Venter Institute, Inc., University of Georgia Research Foundation, and others to provide...
<p>This is a $205,003,103.62 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Modex Therapeutics, Inc. to advance the development of potent, cross-reactive multispecific antibodies for the preparedness countermeasure of COVID-19 and seasonal and highly pathogenic avian influenza. The contract has an ultimate completion date of January 18, 2030. This award is not a set-aside contract.</p>